NEW YORK (GenomeWeb News) – Cellectis today announced two licensing agreements with Iowa State University granting the Paris-based genome engineering firm the rights to use inventions related to TAL effector-nucleases and monomeric TALENs.
The licenses allow Cellectis to use the technology in any field, it said. TALENs are sequence-specific DNA scissors that can be custom engineered to target and modify any gene of interest in any species.
The technology allows for more efficient and targeted methods for DNA recognition and cleavage in the genome of any species, said Cellectis, and has broad applications in genome engineering, such as genetic research, crop improvement, and treatment of human genetic diseases.
TALENs are already integrated into Cellectis's DNA Nuclease production platform.
"Cellectis' R&D teams are already applying these technologies for our programs, and we are extending our offerings to a wider range of innovative first-in-class services and research reagents based on it," Cellectis CEO Andre Choulika said in a statement.
Financial and other terms were not disclosed.